Rigel Pharmaceuticals (RIGL) Total Non-Current Liabilities (2010 - 2025)

Rigel Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $122.1 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities fell 21.56% year-over-year to $122.1 million; the TTM figure through Dec 2025 stood at $122.1 million (down 21.56% YoY), while the FY2025 annual figure was $122.1 million, down 21.56% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $122.1 million, up from $119.9 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $158.5 million in Q1 2021, with the low at $66.9 million in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $118.6 million (2025), against an average of $118.6 million.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities tumbled 49.38% in 2022, then surged 62.03% in 2023.
• Rigel Pharmaceuticals' Total Non-Current Liabilities stood at $84.2 million in 2021, then increased by 25.41% to $105.6 million in 2022, then advanced by 0.28% to $105.9 million in 2023, then jumped by 46.98% to $155.7 million in 2024, then retreated by 21.56% to $122.1 million in 2025.
• Business Quant data shows RIGL's Total Non-Current Liabilities at $122.1 million in Q4 2025, $119.9 million in Q3 2025, and $119.8 million in Q2 2025.